Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.45 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 12/20 | 0.44 |
| ▸ | CA2 | P00918 | 12/20 | 0.44 |
| ▸ | CA4 | P22748 | 12/20 | 0.44 |
| ▸ | CA9 | Q16790 | 12/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8235955 | 0.95 | ABHD6 (0.44) | ABHD6DAGLACA1CA2CA4 | |
| SCHEMBL8237252 | 0.93 | ABHD6 (0.46) | ABHD6DAGLACA1CA2CA4 | |
| SCHEMBL8235760 | 0.92 | ABHD6 (0.46) | ABHD6DAGLAEGFRSRCPARP1 | |
| SCHEMBL8240234 | 0.92 | ABHD6 (0.46) | ABHD6DAGLAEGFRSRCPARP1 | |
| SCHEMBL8238426 | 0.90 | ABHD6 (0.47) | ABHD6DAGLACA1CA2CA4 | |
| SCHEMBL8230155 | 0.89 | ABHD6 (0.45) | ABHD6DAGLACA1CA2CA4 | |
| SCHEMBL8235741 | 0.89 | ABHD6 (0.45) | ABHD6DAGLACA1CA2CA4 | |
| SCHEMBL13340905 | 0.89 | ABHD6 (0.45) | ABHD6DAGLACA1CA2CA4 | |
| SCHEMBL13705167 | 0.89 | ABHD6 (0.47) | ABHD6DAGLACA1CA2CA4 | |
| SCHEMBL3495075 | 0.89 | CA1 (0.49) | CA1CA2CA4CA9ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | ABHD6 2780/4885DAGLA 4388/4885CA1 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.